Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

Anne Chiang, MD, PhD
Published: Thursday, Aug 31, 2017



Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

The toxicities are similar to what is expected with each drug alone, explains Chiang. Around 70% of patients had treatment-related adverse events (AEs), but many of the toxicities could be easily managed. However, 10% of patients discontinued treatment due to the AEs.



Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

The toxicities are similar to what is expected with each drug alone, explains Chiang. Around 70% of patients had treatment-related adverse events (AEs), but many of the toxicities could be easily managed. However, 10% of patients discontinued treatment due to the AEs.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x